Craneware’s (CRW) “Buy” Rating Reiterated at UBS Group

UBS Group restated their buy rating on shares of Craneware (LON:CRW) in a research note released on Wednesday morning, Marketbeat.com reports. They currently have a GBX 570 price target on the stock.

Other equities analysts have also issued research reports about the stock. Shore Capital Group reissued a “buy” rating and issued a GBX 2,850 price target on shares of Craneware in a research report on Tuesday, January 20th. Berenberg Bank reaffirmed a “buy” rating and set a GBX 2,900 price objective on shares of Craneware in a report on Tuesday, January 20th. Four equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of GBX 2,297.75.

Craneware Stock Performance

Shares of LON CRW opened at GBX 1,325 on Wednesday. The business’s 50-day simple moving average is GBX 1,523.15 and its 200-day simple moving average is GBX 1,931.31. The company has a debt-to-equity ratio of 7.93, a quick ratio of 1.00 and a current ratio of 0.76. Craneware has a 52 week low of GBX 1,290 and a 52 week high of GBX 2,644. The firm has a market cap of £470.49 million, a price-to-earnings ratio of 24.00 and a beta of 0.28.

About Craneware

For over 25 years, The Craneware Group (AIM:CRW.L) has been a leader in healthcare financial and operational transformation, delivering cutting-edge technologies that drive measurable impact. Our Trisus® cloud ecosystem unifies data, revenue intelligence, margin intelligence, and advanced analytics, enabling healthcare organizations to optimize performance, improve financial sustainability, and drive strategic growth. As a trusted Microsoft partner, we provide future-ready solutions-including the Best in KLAS Trisus Chargemaster – that simplify the complexities of healthcare finance and operations.